Previous close | 0.4300 |
Open | 0.4348 |
Bid | 0.4170 x 800 |
Ask | 0.4198 x 2200 |
Day's range | 0.4251 - 0.4450 |
52-week range | 0.3840 - 1.0500 |
Volume | |
Avg. volume | 2,584,395 |
Market cap | 229.844M |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.63 |
Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have announced a significant extension of the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversen
GERMANTOWN, Md., March 08, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes ("ATTD") in Florence, Italy.
GERMANTOWN, Md., March 06, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.